Current and Future Drug Targets in Weight Management 119. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther. 2008;117:207–31. 120. Smith SR. Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women. Obesity (Silver Spring). 2009;17:494–503. 121. Arena Pharmaceuticals. Arena pharmaceuticals submits new drug application to FDA for lorcaserin for weight management. December 2009. http://invest.arenapharm.com/releases.cfm? Year=&ReleasesType=&PageNum=2. 122. Thanos PK, Michaelides M, Ho CW, et al. The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity. Pharmacol Biochem Behav. 2008;89:499–507. 123. Adan RA. The MC4 receptor and control of appetite. Br J Pharmacol. 2006;149:815–27. 124. Van der Ploeg LH. Design and synthesis of (ant)-agonists that alter appetite and adiposity. Prog Brain Res. 2006;153:107–18. 125. Jeon MK, Cheon HG. Promising strategies for obesity pharma- cotherapy: Melanocortin-4 (MC-4) receptor agonists and mela- nin concentrating hormone (MCH) receptor-1 antagonists. Curr Top Med Chem. 2009;9:504–38. 126. Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009;86:659–66. 127. Méndez-Andino JL, Wos JA. MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today. 2007;12:972–9. 128. Esbenshade TA, Fox GB, Cowart MD. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol Interv. 2006;6:77–88. 129. Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today. 2009;14:509–15. 130. Yoshimoto R, Miyamoto Y, Shimamura K, et al. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci. 2006;103:13866–71. 131. Barak N, Greenway FL, Fujioka K, Aronne LJ, Kushner RF. Effect of histaminergic manipulation on weight in obese adults: a randomized placebo controlled trial. Int J Obes (Lond). 2008;32:1559–65. 132. Guan X-M, Chen H, Dobbelaar PH, et al. Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab. 2010;11:101– 12. 133. Banno R, Zimmer D, De Jonghe BC, et al. PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice. J Clin Investig. 2010;120:720–34. 134. Lantz KA, Hart SGE, Planey SL, et al. Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet- induced obese mice. Obesity. 2010. 135. Roitman MF, Wescott S, Cone JJ, McLane MP, Wolfe HR. MSI-1436 reduces acute food intake without affecting dopamine transporter activity. Pharmacol Biochem Behav. 2010. 136. Tam S, Saiah E. Recent advances in the discovery and development of PTP-1B inhibitors. Drugs Future. 2008;33:175–85. 137. Tseng Y-H, Cypess AM, Kahn CR. Cellular bioenergetics as a target for obesity therapy. Nat Rev Drug Discov. 2010;9:465–82. 138. Cypess AM. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509–17. 139. Marken Lichtenbelt WD. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500–8. 1817 140. Virtanen KA. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518–25. 141. Arch JR. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from Î23-adrenoceptor agonists. Naunyn-Schmiedeberg’s Arch Phar- macol. 2008;378:225–40. 142. Frühbeck G, Becerril S, Sáinz N, Garrastachu P, García-Velloso MJ. BAT: a new target for human obesity? Trends Pharmacol Sci. 2009;30:387–96. 143. Larsen TM, Toubro S, Van Baak MA, et al. Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr. 2002;76:780–8. 144. Redman LM, De Jonge L, Fang X, et al. Lack of an effect of a novel β3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo- controlled randomized study. J Clin Endocrinol Metab. 2007; 92:527–31. 145. Bryzgalova G. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor β subtype selective agonist KB- 141. J Steroid Biochem Mol Biol. 2008;111:262–7. 146. Scanlan TS. Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail Rev. 2010;15: 177–82. 147. Villicev CM. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol. 2007;193:21–9. 148. Morton NM. Obesity and corticosteroids: 11[beta]-Hydroxyste- roid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol. 2010;316:154–64. 149. Nawrocki AR, Scherer PE. Keynote review: the adipocyte as a drug discovery target. Drug Discov Today. 2005;10:1219– 30. 150. Wang M. Glucocorticoid antagonists and 11[beta]-HSD1 inhibitors. Drug Discov Today Ther Strat. 2007;4:117–22. 151. Wamil M, Seckl JR. Inhibition of 11ß-hydroxysteroid dehydro- genase type 1 as a promising therapeutic target. Drug Discov Today. 2007;12:504–20. 152. Gathercole LL, Stewart PM. Targeting the pre-receptor metab- olism of cortisol as a novel therapy in obesity and diabetes. J Steroid Biochem Mol Biol. 2010 (In Press). doi:10.1016/j.j sbmb.2010.03.060. 153. Véniant MM, Hale C, Hungate RW, et al. Discovery of a potent, orally active 11Î²-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S, 2S, 4 R)-Bicyclo [2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221). J Med Chem. 2010;53:4481–7. 154. Fotsch C, Wang M. Blockade of glucocorticoid excess at the tissue level: inhibitors of 11β-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes. J Med Chem. 2008;51:4851– 7. 155. Su X, Pradaux-Caggiano F, Thomas MP, et al. Discovery of adamantyl ethanone derivatives as potent 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors. ChemMedChem. 2010;5:1026–44. 156. Tiwari A. INCB-13739, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes. IDrugs. 2010;13:266–75. 157. Baur JA. Biochemical effects of SIRT1 activators. Biochim Biophys Acta: Proteins Proteomics. 2010;1804:1626–34. 158. Jiang W-J. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun. 2008; 373:341–4. 159. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450:712–6.